AZN · AstraZeneca PLC Ordinary Shares
View on chartInsiders & Stakes
| Sharma Mani See remarks | ▲ Buy | Grant | 19,291 Shares held | 10/6/2026 | View profile |
Transaction History
| Sharma Mani | ▲ Buy | Grant | 2 | $320 | 10/6/2026 |
| Sharma Mani | ▲ Buy | Grant | 1 | $163 | 9/8/2026 |
| Sharma Mani | ▲ Buy | Open Market | 20 | $3K | 8/8/2026 |
| Sharma Mani | ▲ Buy | Grant | 2 | $327 | 8/6/2026 |
| Sharma Mani | ▲ Buy | Grant | 2 | $381 | 7/6/2026 |
| Sharma Mani | ▲ Buy | Grant | 1 | $180 | 6/8/2026 |
| Sharma Mani | ▼ Sell | Open Market | 11,893 | $2.2M | 5/20/2026 |
| Sharma Mani | ▲ Buy | Grant | 1 | $186 | 5/6/2026 |
| Sharma Mani | ▲ Buy | Grant | 1 | $196 | 4/7/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AZN Announces AI Drug Discovery Partnership and Trial Outlook
AstraZeneca disclosed a new partnership with insitro to use artificial intelligence for drug discovery in MASH and cardiomyopathies. The collaboration aims to accelerate early‑stage research and could expand the company's pipeline. Around the same time, RBC reaffirmed an outperform rating ahead of the AVANZAR lung‑cancer trial, while the stock outperformed the broader market in recent trading. These developments add focus to both innovative research and upcoming clinical data.
AZN Announces AI Drug Discovery Partnership and Trial Outlook. AstraZeneca disclosed a new partnership with insitro to use artificial intelligence for drug discovery in MASH and cardiomyopathies. The collaboration aims to accelerate early‑stage research and could expand the company's pipeline. Around the same time, RBC reaffirmed an outperform rating ahead of the AVANZAR lung‑cancer trial, while the stock outperformed the broader market in recent trading. These developments add focus to both innovative research and upcoming clinical data.